Tratamiento con estatinas en pacientes dislipidémicos mayores de 75 años, en prevención primaria

  1. R. Palomo-Rodríguez 1
  2. J.A. Ortega-Blanco 1
  3. M. Pedregal-González 2
  4. R. Serrano-Nogales 3
  1. 1 Centro de Salud Molino de la Vega, Huelva, España
  2. 2 Unidad Docente de Medicina Familiar y Comunitaria, Huelva, España
  3. 3 Ginecología, Hospital Juan Ramón Jiménez, Huelva, España
Show affiliations +
Journal:
Semergen: revista española de medicina de familia

ISSN: 1138-3593

Year of publication: 2020

Issue: 7

Pages: 464-471

Type: Article

DOI: 10.1016/J.SEMERG.2020.04.006 DIALNET GOOGLE SCHOLAR

More publications in: Semergen: revista española de medicina de familia

Abstract

Objectives To determine possible differences in the incidence of cardiovascular events between dyslipidaemia patients older than 75 years treated with statins compared to those not treated with them, as primary prevention. Material and methods A retrospective cohort study was conducted in patients older than 75 years with dyslipidaemia in a health centre, between 2005 and 2015. The study included 329 patients (182 on treatment with statins and 147 with no lipid-lowering treatment) who met the inclusion criteria (patients older than 75 years, on treatment with statins for at least 3 years, or to have not had any lipid lowering treatment and as primary prevention). The study variables were all those considered as a risk factor in the latest cardiovascular risk guidelines, and the dependent variable was “cardiovascular event”. A descriptive and inferential analysis was carried out for quantitative and qualitative variables, as well as a multivariate analysis using binary logistic regression. Results The incidence of cardiovascular events in patients without treatment with statins was 15.93% (95% CI 11.15-21.80), and 37.42% (95% CI 29.87-45.45) in those that were taking them (P < .001). The RR was 2.35 (95% CI 1.58-3.48). Conclusions There are statistically significant differences, with an increase in the incidence of cardiovascular events in patients taking statins, compared to those who do not. It is currently considered whether real importance is being given to cholesterol levels in this patient group, as well as whether the prescription of statins in patients older than 75 years is suitable in primary prevention.

Bibliographic References

  • J. Millán, E. Alegría, L. Alvarez-Sala, J. Ascaso, C. Lahoz, T. Mantilla, et al. Documento Abordaje de la dislipidemia. Sociedad Española de Arteriosclerosis (parte iii) Clin Invest Arterioscl., 24 (2012), pp. 102-107 Google Scholar
  • Quinto Grupo de Trabajo de la Sociedad Europea de Cardiología y otras Sociedades sobre la Prevención de la Enfermedad Cardiovascular en la Práctica Clínica Guía europea sobre prevención de la enfermedad cardiovascular en la práctica clínica Rev Esp Cardiol., 65 (2012), pp. 937.e1-937.e66 Google Scholar
  • Stone NJ, Robinson JG, Lichtenstein AH, Bairey-Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA Guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889-934. Google Scholar
  • The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice 2016 European guidelines on cardiovascular disease prevention in clinical practice Eur Heart J, 37 (2016), pp. 2315-2381 Disponible en: http://eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw106 Google Scholar
  • A. Maiques, M. Franch, C. Fluixá Estatinas: eficacia, seguridad e indicaciones Inf Ter Sist Nac Salud, 28 (2004), pp. 89-100 Google Scholar
  • Millán J, Díaz A, Blasco M, Pérez F. Guía clínica para la detección, diagnóstico y tratamiento de la dislipemia aterogénica en Atención Primaria. Barcelona: Sociedad Española de Medicina de Familia y Comunitaria; 2013. Disponible en: www.researchgate.net/publication/271487079 Google Scholar
  • R. Estruch, E. Ros Primary prevention of cardiovascular disease with a Mediterranean diet N Engl J Med, 368 (2013), pp. 1279-1290 Disponible en: https://www.nejm.org/doi/full/10.1056/NEJMoa1200303 CrossRefView Record in ScopusGoogle Scholar
  • L.C. Baptista, M.T. Veríssimo, R.A. Martins Statin combined with exercise training is more effective to improve functional status in dyslipidemic older adults Scand J Med Sci Sports, 28 (2018), pp. 2659-2667 CrossRefView Record in ScopusGoogle Scholar
  • D. Fierro González Tratamiento del anciano con dislipemia Semergen, 40 (Supl 1) (2014), pp. 17-21 Google Scholar
  • T.E. Strandberg, L. Kolehmainen, A. Vuorio Evaluation and treatment of older patients with hypercholesterolemia: A clinical review JAMA, 312 (2014), pp. 1136-1144 CrossRefView Record in ScopusGoogle Scholar
  • F. Retornaz, S. Beliard, E. Gremeaux, L. Chiche, L. Lagarde, M. Andrianasolo, et al. [Statin and cardiovascular diseases after 75 years] French Rev Med Interne, 37 (2016), pp. 625-631 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • R. Gómez-Huelgas, M. Martínez-Sellés, F. Formiga, J.J. Alemán Sánchez, M. Camafort, E. Galve, et al. Tratamiento de los factores de riesgo vascular en el paciente mayor de 80 años Med Clin (Barc), 143 (2014), pp. 134.e1-134.e11 ArticleDownload PDFGoogle Scholar
  • Cholesterol Treatment Trialists’ Collaboration Efficacy and safety of statin therapy in older people: A meta-analysis of individual participant data from 28 randomised controlled trials Lancet, 393 (2019), pp. 407-415 Google Scholar
  • P. Giral, A. Neumann, A. Weill, J. Coste Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: A nationwide population-based cohort study in France Eur Heart J, 40 (2019), pp. 3516-3525, 10.1093/eurheartj/ehz458 CrossRefView Record in ScopusGoogle Scholar
  • J. Shepherd, G.J. Blauw, M.B. Murphy, E.L. Bollen, B.M. Buckley, S.M. Cobbe, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial Lancet, 360 (2002), pp. 1623-1630 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • P.S. Sever, B. Dahlof, N.R. Poulter, H. Wedel, G. Beevers, M. Caulfield, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial Lancet, 361 (2003), pp. 1149-1158 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • T. Jackson, M. Wright Jr., L. Jeffrey, M. Probstfield, C. William, M. Cushman, et al. ALLHAT findings revisited in the context of subsequent analyses, other trials and meta-analyses Arch Intern Med., 169 (2009), pp. 832-842 CrossRefView Record in ScopusGoogle Scholar
  • F. Mach, C. Baigent, A.L. Catapano, K.C. Koskinas, M. Casula, L. Badimon, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk Eur Heart J, 41 (2020), pp. 111-188 CrossRefView Record in ScopusGoogle Scholar
  • American Diabetes Association Classification and diagnosis of diabetes: Standards of medical care in diabetes--2019 Diabetes Care., 42 (Suppl 1) (2019), pp. S13-S28 https://doi.org/10.2337/dc19-s002 Google Scholar
  • R. Ramos, M. Comas-Cufí, R. Martí-Lluch, E. Balló, A. Ponjoan, L. Alves-Cabratosa, et al. Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: Retrospective cohort study BMJ., 362 (2018), p. k3359 CrossRefGoogle Scholar
  • A.D. Sniderman, S. Islam, M. McQueen, M. Pencina, C.D. Furberg, G. Thanassoulis, et al. Age and cardiovascular risk attributable to apolipoprotein B, low-density lipoprotein cholesterol or non-high-density lipoprotein cholesterol J Am Heart Assoc., 5 (2016), p. e003665 CrossRefGoogle Scholar
  • M.T. Mc Auley, K.M. Mooney LDL-C levels in older people: Cholesterol homeostasis and the free radical theory of ageing converge Med Hypotheses., 104 (2017), pp. 15-19 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • J.M. Jacobs, A. Cohen, E. Ein-Mor, J. Stessman Cholesterol, statins, and longevity from age 70 to 90 years J Am Med Dir Assoc., 14 (2013), pp. 883-888 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • I.V. Osipova, N.V. Pyrikova, O.N. Antropova, I.N. Komissarova, A.I. Miroshnichenko [Effect of psychosocial stress on the level of anxiety, depression and behavioral risk factors of cardiovascular diseases in men] Russian Kardiologiia, 54 (2014), pp. 42-45 CrossRefView Record in ScopusGoogle Scholar
  • M.A. Albert, E.M. Durazo, N. Slopen, A.M. Zaslavsky, J.E. Buring, T. Silva, et al. Cumulative psychological stress and cardiovascular disease risk in middle aged and older women: Rationale, design, and baseline characteristics Am Heart J., 192 (2017), pp. 1-12 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • S. Stringhini, C. Carmeli, M. Jokela, M. Avendaño, C. McCrory, A. d’Errico, et al., LIFEPATH Consortium Socioeconomic status, non-communicable disease risk factors, and walking speed in older adults: Multi-cohort population based study BMJ., 360 (2018), p. k1046 CrossRefGoogle Scholar
Data source: Dialnet